TORONTO, Nov. 30, 2021 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to announce that the Japan Patent Office has issued Japanese Patent No. 6967532 for KETABET , a combination formulation of FDA-approved ketamine and betaine anhydrous, which has shown in research to enhance the…


Previous articlePT275 – James Fadiman, Ph.D. – Transpersonal Psychology, Microdosing, and Your Symphony of Selves
Next articleIbogaine and Cardiac Arrhythmia: The Heart of the Matter